RT Journal Article
SR Electronic
T1 Imaging of Pheochromocytoma and Paraganglioma
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1033
OP 1042
DO 10.2967/jnumed.120.259689
VO 62
IS 8
A1 Jorge A. Carrasquillo
A1 Clara C. Chen
A1 Abhishek Jha
A1 Alexander Ling
A1 Frank I. Lin
A1 Daniel A. Pryma
A1 Karel Pacak
YR 2021
UL http://jnm.snmjournals.org/content/62/8/1033.abstract
AB Imaging plays a critical role in the management of pheochromocytomas and paragangliomas and often guides treatment. The discovery of susceptibility genes associated with these tumors has led to better understanding of clinical and imaging phenotypes. Functional imaging is of prime importance because of its sensitivity and specificity in subtypes of pheochromocytoma and paraganglioma. Several radiopharmaceuticals have been developed to target specific receptors and metabolic processes seen in pheochromocytomas and paragangliomas, including 131I/123I-metaiodobenzylguanidine, 6-18F-fluoro-l-3,4-dihydroxyphenylalanine, 18F-FDG, and 68Ga-DOTA-somatostatin analogs. Two of these have consequently been adapted for therapy. This educational review focuses on the current imaging approaches used in pheochromocytomas and paragangliomas, which vary among clinical and genotypic presentations.